$EVO (-12.9% pre) Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance https://t.co/oZ9NrNn98L
$EVO - Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix - https://t.co/mcbnY5MWkL
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix $EVO https://t.co/az1ZqjjsgV
Evotec SE cut its fiscal-year 2025 revenue forecast to €760–800 million, down from the prior €840–880 million range, after first-half sales in its Shared R&D business fell short of expectations. Despite the lower top-line projection, the Hamburg-based drug-discovery company kept its adjusted EBITDA goal at €30–50 million and maintained planned R&D spending of €40–50 million, saying a richer mix of high-margin technology licence income will support profitability. Management said the company’s “Priority Reset” cost-optimisation programme is delivering savings ahead of schedule, helping offset weaker volumes. Evotec, which is moving to a capital-lighter model, affirmed longer-term goals for 8–12% compound annual revenue growth and an adjusted EBITDA margin above 20% by 2028. The shares fell roughly 13% in Frankfurt pre-market trading following the guidance revision.